Brunella Gonzalez Cautela, M.Sc.A. Clinical Research Specialist at the Rosell® Institute from Microbiome and Probiotics by Lallemand, will open the Sociedad Española de MICROBIOTA, Probióticos y Prebióticos (SEMiPyP) congress, which will be held from September 15 to 18, 2021, in Madrid, Spain.
The aim of the presentation is to share the findings of the Metabolic Health Management study Supplementation with Lacticaseibacillus rhamnosus HA-114 as an adjuvant during a weight-loss nutritional intervention among people with obesity/overweight (WMUL study) carried at the University Laval in Quebec, Canada.
“We are thrilled of the outcomes of this breakthrough study in overweight adults on a weight loss program”, announces Ms. Brunella Gonzalez Cautela. At the congress I will talk in detail about the impact of a probiotic supplementation on the response of overweight individuals to a weight-reducing program. We had incredible results highlighting the beneficial effects of the probiotic intervention on eating behaviors, mental health, and metabolic profile. These results reinforce the validity of the brain-gut axis concept and warrants the influence of probiotics on psychological wellbeing among participants enrolled in a caloric-restriction intervention. You don’t want to miss this”, she concludes.
Taken place virtually, with live and on-demand activities, SEMiPyP Congress is dedicated to the promotion and dissemination of scientific knowledge and clinical application around the microbiota, probiotics and prebiotics. In this joint meeting, various national and international experts will address many topics of interest that will be possible to enjoy live or outside of direct hours. For more information visit the conference website
About Brunella Gonzalez Cautela, M.Sc.A.
Brunella Gonzalez Cautela is a Clinical Research Specialist within the Clinical Program at the Rosell® Institute from Microbiome and Probiotics by Lallemand. Brunella holds a master’s degree in Biotechnology from McGill University, and a bachelor’s degree in Behavioural Neuroscience from Concordia University, Montreal, Canada. This academic background grants Brunella with multidisciplinary skills and remarkable versatility. Her main role within the clinical team is to manage and coordinate clinical trials of the Lallemand Health Solutions portfolio, from their conception to the end. Brunella’s main interests are the effects of probiotics on the enteric and central nervous systems, as well as the potential use of probiotics as adjuvant therapy in mental disorders.
About The Rosell® Institute for Microbiome and Probiotics by Lallemand
Lallemand Health Solutions’ research and development center located at the National Research Council of Canada in Montreal, develops partnerships with key scientific experts to study the human microbiome and how probiotic supplements can be used to improve or maintain health in specific populations or health segments. The research team has issued over 330 publications including 160 clinical studies.
Lallemand Health Solutions is a privately-owned Canadian company that researches, manufactures, and markets probiotic bacteria and yeast to nutritional and pharmaceutical companies that sell to the consumer and is a global leader of the probiotic industry with 600 formulas distributed in more than 60 countries. Lallemand Health Solutions is a research driven company and has an interest in innovative tools to evaluate the beneficial effect of probiotics in the human body and to understand the mechanisms of action of these microorganisms.
Lallemand Health Solutions
Marilou Luneau email@example.com